Search
moon
sun

T127. Wheezing in infants and children

A. Introduction

1.
Wheeizng : High-pitched sound d/t elevation of airway resistance d/t obstructive process (1) Stridor : Upper airway obstruction (above the thoracic inlet), marked inspiration (2) Wheezing : Lower airway obstruction (distal to the thoracic inlet), marked expiration

B. Respiratory physiology

โ€ข
Diffuse(asthma, bronchiolitis) or focal(foreign body) intrathoracic airway obstruction์ด ์žˆ์œผ๋ฉด ๊ธฐ๋„์ €ํ•ญ์„ ๊ทน๋ณตํ•˜๊ธฐ ์œ„ํ•ด ๋ณต๊ทผ ๋ฐ intercostal muscle์„ ์‚ฌ์šฉํ•˜๊ฒŒ ๋œ๋‹ค.
โ‡’ ๊ทธ๋Ÿฌ๋ฉด Intrapleural pressure์˜ ์–‘์••์ด ๊ฑธ๋ฆฌ๊ณ  ์ด๊ฒƒ์€ ๊ธฐ๋„์— ๋” ์ €ํ•ญ์„ ๊ฐ€ํ•˜๊ฒŒ ๋˜์–ด dynamic airway compression์ด ๋ฐœ์ƒํ•œ๋‹ค.
โ‡’ Dynamic aiway compromise๋Š” ๊ฒฐ๊ตญ ํ˜ธ๊ธฐ์‹œ๊ฐ„์„ ๊ธธ๊ฒŒ ํ•˜์—ฌ end expiration ๋•Œ alveoli์— air traping์„ ์ดˆ๋ž˜ํ•˜๊ณ  ์ด๊ฒƒ์€ ๋‹ค์Œ ํ˜ธํก cycle์—์„œ auto-peep์„ ์œ ๋ฐœํ•˜์—ฌ VQ mismatch, hypoxemia๋ฅผ ์œ ๋ฐœํ•œ๋‹ค.

C. Wheezing

โ€ข
6์„ธ ํ™˜์•„์˜ ์•ฝ 50%๋Š” wheezing์„ ๊ฒฝํ—˜ํ•œ๋‹ค
โ€ข
2์„ธ ์ด์ƒ ํ™˜์•„ : Recurrent or episodic pattern, trigger์™€์˜ ์—ฐ๊ด€์„ฑ, bronchodilator effect๊ฐ€ ์žˆ๋Š” ๊ฒƒ์€ asthma์˜ ๊ฐ€๋Šฅ์„ฑ์„ ํฌ๊ฒŒ ์‹œ์‚ฌ
โ€ข
1์„ธ ๋ฏธ๋งŒ : Viral season ๋™์•ˆ sick contact, nasal congestion, poor feeding์€ bronchiolitis๋ฅผ ์‹œ์‚ฌ

C1. Clinical features

(1) P/ex assessment triangle : Appearance, Work of breathing and Circulation

โ€ข
General appearance : TICLS (Tone, Interactivity, Consolability, Look, and Speech)
โ€ข
Work of Breathing : position(sniffing,tripod), accessory m. use, stridor or wheeze
โ€ข
Circulation : cyanosis
โ€ข
Respiratory rate : Table 127-2 ์ฐธ์กฐ. ๊ผญ 1๋ถ„ Full๋กœ ์žด ๊ฒƒ.
โ€ข
Mild hypoxemia (92-94%) ๏ผšSupplemental O2 ํ•„์š”ํ•จ. <92% ์ดํ•˜์˜ hypoxemia๋Š” moderate severe disease ์‹œ์‚ฌ
โ€ข
Diaphoresis, confusion and drowsiness ์žˆ์œผ๋ฉด imminent respiratory failure!
โ€ข
Inspiratory-to-expiratory ratio๊ฐ€ ์ •์ƒ์ธ 2:1๋ณด๋‹ค ์ž‘์œผ๋ฉด (eg., 1:2, 1:3) obstructive ์‹œ์‚ฌ!
โ€ข
์ฒซ p/ex finding๋ณด๋‹ค Bronchodilator ์“ด ํ›„์— ํšจ๊ณผ๊ฐ€ ์žˆ๋Š”์ง€๊ฐ€ ์ค‘์š”ํ•จ.

C2. Diagnosis

โ€ข
Table 127-3 (1) Asthma, bronchiolitis๊ฐ€ wheezing์„ ๋ณด์ด๋Š” ํ™˜์•„์—์„œ ์ง„๋‹จ์˜ ๋Œ€๋ถ€๋ถ„์„ ์ฐจ์ง€ํ•˜๋‚˜ history, p/ex, ์ถ”๊ฐ€ ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด ๋‹ค๋ฅธ ๊ฐ๋ณ„ ์ง„๋‹จ๋“ค๋„ ๋ฐ˜๋“œ์‹œ ๊ณ ๋ คํ•ด์•ผ ํ•œ๋‹ค. (2) ์ด๋ฌผ ํก์ธ์ด๋‚˜ ์šธํ˜ˆ์„ฑ ์‹ฌ๋ถ€์ „๋„ ๋˜ํ•œ wheezing์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค.

C3. Bronchiolitis (โ˜…)

(1) ์—ญํ•™

โ€ข
2์„ธ ์ดํ•˜ ํ™˜์•„์—์„œ ๊ฐ€์žฅ ํ”ํ•œ ํ•˜๊ธฐ๋„ ๊ฐ์—ผ์งˆํ™˜
โ€ข
11์›”~3์›”์— ๊ฐ€์žฅ ๋งŽ์ด ๋ฐœ์ƒ (๋ถ์•„๋ฉ”๋ฆฌ์นด๊ธฐ์ค€)
โ€ข
๊ฐ€์žฅ ํ”ํ•œ ์›์ธ ๋ฐ”์ด๋Ÿฌ์Šค : Respiratory syncytial virus (RSV) ๊ทธ ์™ธ : human metapneumovirus, adenovirus, influenza,rhinovirus and parainfluenza viruses

(2) ์ฆ์ƒ/์ง•ํ›„

โ€ข
Rhinorrhea, Tachypnea, Fever, coughing
โ€ข
Use of accessory muscles, Nasal flaring, Wheezing
โ€ข
ํ‰๊ท  7์ผ~21์ผ๊ฐ„ ์ง€์† ๊ฐ€๋Šฅ. ์ฆ์ƒ์€ ์ฒซ ์ฃผ์— ๊ฐ€์žฅ ์‹ฌํ•จ
โ€ข
์•„์ฃผ ์–ด๋ฆฐ ์†Œ์•„์—์„  Irritability, cyanosis, poor feeding (WOB์ฆ๊ฐ€๋กœ) ์ฆ์ƒ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค

(3) ์ง„๋‹จ

โ€ข
์ž„์ƒ์–‘์ƒ์œผ๋กœ ์ง„๋‹จํ•œ๋‹ค : 2์„ธ ๋ฏธ๋งŒ์—์„œ ํŠน์ง•์  ์ฆ์ƒ/์ง•ํ›„๋ฅผ ๋ณด์ด๋Š” ๊ฒฝ์šฐ์— ์˜์‹ฌ
โ€ข
Rapid viral antigen detection๋„ ์ง„๋‹จ์— ๋„์›€์ด ๋˜์ง€ ์•Š์Œ.
โ€ข
lab, X-ray ๋„ ๋‹ค๋ฅธ ์งˆํ™˜ ๋ฐฐ์ œ๊ฐ€ ํ•„์š”ํ•˜์ง€ ์•Š๋‹ค๋ฉด routine์œผ๋กœ ํ•„์š”ํ•˜์ง€ ์•Š์Œ.
โ€ข
Chest X-ray๋ฅผ routine์œผ๋กœ ํ•˜์ง€๋Š” ์•Š์ง€๋งŒ severe hypoxia๊ฐ€ ์žˆ๊ฑฐ๋‚˜ pneumothorax๊ฐ€ ์˜์‹ฌ๋  ๋•Œ๋Š” ์‹œํ–‰์„ ๊ณ ๋ คํ•ด๋ณผ ์ˆ˜ ์žˆ๋‹ค.

(8) ์น˜๋ฃŒ(โ˜…)

โ€ข
๊ฐ€์žฅ ์ค‘์š”ํ•œ Tx. : ์ž์ฃผ ์ƒ๋ฆฌ์‹์—ผ์ˆ˜ ๋น„๊ฐ•์„ธ์ฒ™ ๋ฐ ํก์ธ
โ€ข
ฮฒ2-agonists (salbutamol/albuterol, ipratropium bromide, terbutaline) : ํšจ๊ณผ ์—†๋‹ค.
โ€ข
Inhaled epinephrine : ์ž…์›์œจ์—๋Š” ๋ณ€ํ™” ์—†์œผ๋‚˜ ์ฆ์ƒ ์™„ํ™”์— ์จ๋ณผ ์ˆ˜ ์žˆ๋‹ค. (routine ์•„๋‹˜)
โ€ข
Dexamethasone(1mg/kg) + inhaled epinephrine์€ routine ํ•˜๊ฒŒ ์“ฐ์ง€๋Š” ๋ง ๊ฒƒ.
โ€ข
Systemic or inhaled steroid alone๋„ ๋Œ€๋ถ€๋ถ„ ๊ฐ€์ด๋“œ๋ผ์ธ์ด ์“ฐ์ง€ ๋ง๋ผ ๋˜์–ด์žˆ์Œ
โ€ข
Nebulized hypertonic saline : ํ•˜์ง€ ๋งˆ๋ผ. (d/t 2014 American Academy of Pediatrics)
โ€ข
Oxygen saturation >90% ๋Š” ์œ ์ง€ํ•  ๊ฒƒ์„ ๊ถŒ๊ณ 
โ€ข
NIV, HFNC๋Š” intubation์ด๋‚˜ MV๋ฅผ ์ค„์—ฌ ์ฃผ๋Š”๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋‹ค.

(9) ๊ฑฐ์ทจ๊ฒฐ์ •

โ€ข
๋Œ€๋‹ค์ˆ˜ ํ™˜์•„๋Š” ํ‡ด์› ๊ฐ€๋Šฅ, ๊ธ‰์„ฑ ์•…ํ™” ์‹œ ์žฌํ‰๊ฐ€ ์œ„ํ•ด ์žฌ๋‚ด์› ๋‹น๋ถ€ / 3์ฃผ๊นŒ์ง€ ์ฆ์ƒ ์ง€์† ๊ฐ€๋Šฅ ์„ค๋ช…
โ€ข
Admission ์ ์‘์ฆ : Table 127-4์— ํ•˜๋‚˜๋ผ๋„ ํ•ด๋‹นํ•˜๋ฉด ์ž…์›์„ ๊ณ ๋ คํ•˜๊ฑฐ๋‚˜ ์‘๊ธ‰์‹ค์—์„œ ๋” ๊ด€์ฐฐํ•˜๊ณ  ๋ณด๋‚ด์•ผ ํ•œ๋‹ค.

C4. Asthma

(1) Chronic disease, Reversible airway obstruction d/t bronchial smooth muscle hyperreactivity and inflammation. (2) Response to bronchodilator and Steroid Tx. (3) Pathophysiology - ํฌ๊ฒŒ 3๊ฐ€์ง€ process โ‘  Inflammation โ‘ก Bronchospasm โ‘ข Airway obstruction (4) Clinical features and initial assessment โ‘  2~18์„ธ์˜ ํ™˜์•„ ์ค‘ 95% ์ด์ƒ์ด wheezing, shortness of breath, fever, cough, and/or dyspnea ๋“ฑ์„ ๋ณด์ธ๋‹ค. โ‘ก Pulse oximetry๋กœ ๋ชจ๋‹ˆํ„ฐํ•˜๋Š” ๊ฒƒ์„ ๊ถŒ๊ณ , Target 93%~98%. ๋„ˆ๋ฌด O2 ๋งŽ์ด ์ฃผ๋ฉด Hypercapnia ์ƒ๊น€. โ‘ข End-tidal carbon dioxide (ETCO2) monitoring ํ•˜๋Š” ๊ฒƒ์ด ์ข‹๋‹ค. ์ •์ƒ์€ 35 to 40mmHg (Asthma ํ™˜์ž๋Š” ์ •์ƒ์ˆ˜์น˜๋ณด๋‹ค ๋‚ฎ์•„์•ผ ์ •์ƒ์ด๋‹ค.) โ‘ฃ ์กฐ์šฉํ•œ ํ์Œ์€ ์˜คํžˆ๋ ค severely compromised ventilation ์‹œ์‚ฌํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ wheezing์„ ๋งŒ๋“ค์–ด๋‚ด์ง€ ๋ชปํ•  ์ •๋„๋กœ ๋ถˆ์ถฉ๋ถ„ํ•œ air flow๋ฅผ ์˜๋ฏธํ•  ์ˆ˜ ์žˆ๋‹ค. โ‘ค Severity : mild, moderate, severe or imminent respiratory failure (Fig 127-3)
(5) Diagnosis โ‘  Asthma ์ง„๋‹จ ๋ฐ›์€ ๋ฐ” ์—†๋Š” 2์„ธ ์ด์ƒ ํ™˜์•„๋Š” ์ฆ‰์‹œ ์ž„์ƒ์ง„๋‹จ์„ ๋‚ด๋ฆฐ๋‹ค : Wheezing, Shortness of breath, Cough, Dyspnea, Diminished air entry or retractions AND Demonstration of reversibility with ฮฒ2-agonist bronchodilators (e.g.salbutamol/albuterol) โ‘ก 1์„ธ~2์„ธ viral-induced wheeze : asthma ๋˜๋Š” bronchiolitis๋กœ ์น˜๋ฃŒ โ‘ข <1์„ธ ํ™˜์•„๋Š” Bronchiolitis๋กœ ๊ฐ„์ฃผ. โ‘ฃ Spirometry ์“ธ๋ชจ ์žˆ์ง€๋งŒ <6์„ธ ํ™˜์•„์—์„œ ์‚ฌ์šฉ ํž˜๋“ฆ, ์ฆ์ƒ์ด ์‹ฌํ•˜๋ฉด ๋ถˆ๊ฐ€,
โ‘ค ์ฒœ์‹์˜ ๊ธ‰์„ฑ์•…ํ™”์— Atelectasis๋Š” ๋งค์šฐ ํ”ํ•˜๋‹ค, Bacterial pneumonia ๋งค์šฐ ๋“œ๋ฌผ๋‹ค. ๊ทธ๋ž˜์„œ table 127-5์— ๋‚˜์˜ค๋Š” indication์ด ์•„๋‹ˆ๋ฉด x-ray๋ฅผ ๊ถŒ๊ณ ํ•˜์ง€๋Š” ์•Š์Œ. โ‘ฅ Indications for chest x-ray :
(6) Treatment
โ‘  SABA : Salbutamol/albuterol is most widely used. : Onset 3~5min, peak 30~120min, duration 2~5hrs : IV dose๋Š” air entry ๋„ˆ๋ฌด ๋–จ์–ด์ ธ ๋„๋‹ฌ ๋ชปํ•  ๋•Œ๋งŒ : Oral albuterol์€ not recommended (delayed onset, tachycardia ๋“ฑ) โ‘ก Epi-pen : ฮฒ-selective medication์ด ์—†์œผ๋ฉด ์จ๋ณผ ์ˆ˜๋Š” ์žˆ๋Š”๋ฐ ํ•˜๊ธฐ๋„์—๋งŒ ์ž‘์šฉํ•˜๋Š” ๊ฒƒ์ด ์•„๋‹ˆ์–ด์„œ short-term side effect๋ฅผ ์ผ์œผํ‚ฌ ์ˆ˜๋Š” ์žˆ๋‹ค. โ‘ข Systemic corticosteroids : Moderate, severe exacerbation ํ™˜์ž์—๊ฒŒ ์ฆ‰์‹œ ํˆฌ์•ฝ๋˜์–ด์•ผ ํ•œ๋‹ค. : ์ž…์›๋ฅ  & ์žฌ๋ฐœ ๊ฐ์†Œ์— ํšจ๊ณผ์  (Onset <4hrs) : Triage nurse๊ฐ€ ๋ฐ”๋กœ ์“ฐ๋ฉด ED length & adm rate ๊ฐ์†Œํ•œ๋‹ค. : ๋‚ด์› 1์‹œ๊ฐ„ ์•ˆ์— Prednisone PO 2mg/kg ์“ฐ๊ณ  ํ‡ด์› ์‹œ 4์ผ๊ฐ„ 1mg/kg/d(max 60mg/d) ์ฒ˜๋ฐฉ (5 day total course) taper not required. : Severly ill, ์น˜๋ฃŒ์— ๋ฐ˜์‘ ์—†์œผ๋ฉด IV methylprednisone(1mg/kg/dose) 6์‹œ๊ฐ„๋งˆ๋‹ค ์ถ”๊ฐ€ : Dexamethasone์€ ๋ง›์žˆ์Œ. PO, IM, IV ๊ฐ€๋Šฅ
โ€ข
Single dose (0.6mg/kg), 2day course(0.6mg/kg/d), 3~5days course(0.2-0.3mg/kg/d) : Inhaled corticosteroid
โ€ข
ED์—์„œ ์—ญํ•  ์—†๋‹ค.
โ€ข
ํ‡ด์› ์‹œ persistent ํ™˜์ž์—๊ฒŒ ์ฒ˜๋ฐฉ for home care
โ‘ฃ Anticholinergic agents(ipratropium bromide)๋Š” SABA์— additive effect๊ฐ€ ์žˆ๋‹ค. โ‘ค Mg์€ bronchodilator ๋กœ ์—ญํ• . IV only (nebulized ํšจ๊ณผ ์—†๋‹ค.) โ‘ฅ Ketamine : Bronchodilation effect๊ฐ€ ์žˆ์–ด asthma๋กœ respiratory failure ์‹œ induction agent๋กœ ์ตœ์ ์ด๋‹ค. (7) Treatment of near-fatal asthma โ‘  Noninvasive positive-pressure ventilation : Well-fitting facemask๋กœ. ์ผ๋ถ€ tolerateํ•˜์ง€ ์•Š์€ ํ™˜์ž์—๊ฒŒ์„œ sedation์ด ํ•„์š”ํ•  ์ˆ˜ ์žˆ์Œ (low dose benzodiazepine or ketamine) : Initial setting์€ severe asthma์˜ ๊ฒฝ์šฐ aPEEP 12~18, PEEP 6~12๋กœ ์„ค์ • : ์—์–ด๋กœ์กธ ์•ฝ๋ฌผ์€ airway circuit์„ ํ†ตํ•ด์„œ ์ฃผ์ž…๋  ์ˆ˜ ์žˆ์Œ
โ‘ก Endotracheal intubation and assisted ventilation
: ๊ฐ€๋Šฅํ•œ ๊ฐ€์žฅ ํฐ ์ง๊ฒฝ์˜ appropriate cuffed ET tube๋ฅผ ์„ ํƒ : Ketamine์ด ์„ ํ˜ธ๋˜๋Š” induction agent์ธ๋ฐ bronchodilation ํšจ๊ณผ๊ฐ€ ์žˆ๊ณ  ์ง์ ‘์ ์ธ BP drop์„ ์ผ์œผํ‚ค์ง€ ์•Š๊ธฐ ๋•Œ๋ฌธ : Controlled hypercapnic hypoventilation์ด ์ถ”์ฒœ๋˜๋Š” ventilator strategy์ด๋‹ค.